Drugs / VS-5584
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02372227 | Jan → Oct 2015 | malignant mesothelioma | Verastem, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT01991938 | Nov 2013 → Dec 2016 | lymphoma, metastatic malignant neoplasm | Verastem, Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VS-5584 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02372227 ↗ |
| Action | Inhibit | “Serine/threonine-protein kinase mTOR inhibitor” CHEMBL3393066 ↗1“VS-5584, a PI3K/mTOR kinase inhibitor” NCT01991938 ↗ |
| Modality | Small molecule | — CHEMBL3393066 ↗ |
| Route | Oral | “Oral VS-5584 administered once daily on Day 1, 3, 5, 8, 10, 12, 15, 17 and 19 of each cycle” NCT01991938 ↗ |
| Target | MTOR | “Serine/threonine-protein kinase mTOR inhibitor” CHEMBL3393066 ↗ |